Aerie Pharmaceuticals : Corporate Presentation – December

Company Overview

Investor Presentation

December 2020

Important Information

The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the "Company" or "Aerie") in this presentation are qualified in their entirety by reference to reports filed with the SEC. Certain information in this presentation has been obtained from outside sources or is anecdotal in nature. While such information is believed to be reliable for the purposes used herein, no representations are made as to the accuracy or completeness thereof and we take no responsibility for such information.

Any discussion of the potential use or expected success of Rhopressa®(netarsudil ophthalmic solution) 0.02% or Rocklatan®(netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, with respect to foreign approval or additional indications, and our current or any future product candidates, including AR-1105,AR-13503 and AR-15512, is subject to regulatory approval. In addition, any discussion of U.S. Food and Drug Administration ("FDA") approval of Rhopressa®or Rocklatan®does not guarantee successful commercialization of Rhopressa®or Rocklatan®. For more information on Rhopressa®, including prescribing information, refer to the full Rhopressa®product label at www.rhopressa.com. For more information on Rocklatan®, including prescribing information, refer to the full Rocklatan®product label at www.rocklatan.com.

The information in this presentation is current only as of its date and may have changed or may change in the future. We undertake no obligation to update this information in light of new information, future events or otherwise. We are not making any representation or warranty that the information in this presentation is accurate or complete. This presentation shall not constitute an offer to sell, nor a solicitation of an offer to buy, any of Aerie's securities.

Certain statements in this presentation, including any guidance or timelines presented herein, are "forward-looking statements" within the meaning of the
federal securities laws. Words such as "may," "will," "should," "would," "could," "believe," "expects," "anticipates," "plans," "intends," "estimates," "targets,"
"projects," "potential" or similar expressions are intended to identify these forward-looking statements. These statements are based on the Company's
current plans and expectations. Known and unknown risks, uncertainties and other factors could cause actual results to differ materially from those
contemplated by the statements. In evaluating these statements, you should specifically consider various factors that may cause our actual results to differ
materially from any forward-looking statements. For example, uncertainties around the duration and severity of the current global COVID-19 pandemic
including its possible impact on our clinical and commercial operations and our global supply chain could cause our actual results to be materially different
than those expressed in our forward-looking statements. In particular, these statements include any discussion of potential commercial sales, placement or
utilization of Rocklatan®or Rhopressa®in the United States or any other market. Likewise, FDA approval of Rhopressa®and Rocklatan®does not
constitute approval of any future product candidates. Any top line data presented herein is preliminary and based solely on information available to us as of
the date of this presentation and additional information about the results may be disclosed at any time. FDA approval of Rhopressa®and Rocklatan®also
does not constitute regulatory approval of Rhopressa®or Rocklatan®in jurisdictions outside the United States and there can be no assurance that we will
receive regulatory approval for Rhopressa®or Rocklatan®in jurisdictions outside the United States. In addition, any discussion in this presentation about
preclinical activities or opportunities associated with our products or discussions involving the potential for our dry eye or retinal product candidates are
preliminary and the outcome of any studies may not be predictive of the outcome of later trials and ultimate regulatory approval. Any future clinical trial
results may not demonstrate safety and efficacy sufficient to obtain regulatory approval related to the preclinical research findings discussed in this
presentation. Any statements regarding Aerie's future liquidity, cash balances or financing transactions also constitute forward-looking statements as are
discussions of the possibility of, or possible results of, any commercial transactions or collaborations. These risks and uncertainties are described more fully
in the quarterly and annual reports that we file with the SEC, particularly in the sections titled "Risk Factors" and "Management's Discussion and Analysis of
Financial Condition and Results of Operations." Such forward-looking statements only speak as of the date they are made. We undertake no obligation to
publicly update or revise any forward-looking statements, whether because of new information, future events or otherwise, except as otherwise required by
law.	2
For Investor Use

Aerie Overview

Aerie IOP-Reducing Products (IP 2030+)

• Rhopressa®and Rocklatan®gaining momentum in the U.S.
• • Total prescriptions and shipments to pharmacies have fully recovered and are growing
• Globalization Plan Under Way- Concluded licensing agreement with Santen for Rhopressa ®and Rocklatan ®; Potential collaborators pursuing European opportunity

Key Pipeline Opportunities

• AR-15512TRPM8 agonist for Dry EyePhase 2b clinical study commenced October 2020
• Sustained-ReleaseImplant Platform:

• RetinaAR-1105 (Positive Topline Phase 2 results reported July 2020)

AR-13503(First-in-human clinical study commenced Q3 2019)

Rhopressa®has not been approved by any regulatory authorities other than the FDA and EMA and Rocklatan®has not been approved by any regulatory authority other
than the FDA. Additional potential Rhopressa®indications are being considered for further study and are not labeled indications. AR-13503 and AR-1105 are	For Investor Use 3
development stage product candidates and are not approved by any regulatory agency.

Aerie's Key Catalysts for 2020

Pipeline:

• SuccessfulAR-1105 Phase 2 RVO clinical study topline readout took place in July 2020
• • Exploring regulatory and commercial pathways forAR-1105
• AR-15512TRPM8 agonist for Dry Eye Phase 2b clinical study commenced in October 2020

Globalization:

• Roclanda®Mercury 3 topline readout in September 2020 successfully achieves non-inferiority
• Positive CHMP opinion received for Roclanda®in November 2020
• • Roclanda®EMA approval expected late 2020 / early 2021
• First Rhopressa®Phase 3 clinical trial in Japan commenced in December 2020

U.S. Glaucoma Franchise: Focus on continued momentum capitalizing on higher coverage

For Investor Use

4

Aerie Overview

2019 U.S. Glaucoma Market

• ~$3B Market, 36M TRx,55M bottles
• 55% of unit volumefirst-line (PGAs)
• 45% of unit volume2-3X/Day Adjuncts

	Rhopressa,	Lumigan,
CAIs, 7%	1%	6%
	Travatan Z,
		4%
AA, 10%

Estimated Glaucoma Market TRx Mix

Other Government,

11%

Commercial & Cash,

30%

Fixed

Combo,

14%

BB, 13%	Latanoprost,
43%
Other PGA,
1%	Graph Source: IQVIA 2019
	CAI: Carbonic Anhydrase Inhibitor
	AA: Alpha Agonist
	BB: Beta Blocker

Medicare Part D &	Aerie's franchise bottles per Rx
Medicaid, 59%	were 1.43 in Q3 2020 (as high
	as 1.46 in recent weeks),
	reflecting an increase in 90
	days' supply.

Sources: IQVIA: NPA Rx and NSP Unit data

For Investor Use

5

Glaucoma Commercialization Focus

• Ongoing communication of the MOST Data and coverage via various communication channels
• • Rhopressa®Coverage: 90% Commercial, 89% Med D
  • Rocklatan®Coverage: 89% Commercial, 56% Med D plus 15% Low Income Subsidy
• Continued execution of the Pulse Strategy, focused on driving monthly prescribers (now 9,000) to weekly prescribers (now 4,500)
• Increasing share of voice with HCP's to further bolster sales momentum
• • Aerie reps calling on top 10,400 highest prescribers
  • Added Contract Sales Organization to call on next 1,400 highest prescribers
  • Added Telesales team to call on next 4,400 highest prescribers

For Investor Use

6

Topline Results from Rhopressa®Phase 4 Multi-centerOpen-label Study (MOST)

• 12-weekMOST study evaluated efficacy, tolerability and safety of Rhopressa®use in 260 patients in a real-world clinical setting
• • Use of Rhopressa®as monotherapy or adjunct was at discretion of the physician
• Used adjunctively (n=151, mITT):
• • Rhopressa®was similarly effective when added to prior PGA monotherapy or when added to prior multi-drug therapy
  • • Additional IOP reductions of 4.3 mmHg and 4.5 mmHg, respectively (12 weeks)
• Used as monotherapy (n=91, mITT):
• • Rhopressa®maintained IOP levels comparable to prior PGA following switch (n=57)
• Rhopressa®was well tolerated as monotherapy and adjunctive therapy
• • Notreatment-related serious adverse events (AEs)
  • Most common AEs were Conjunctival Hyperemia (20.8%) and Vision Blurred (7.3%)
  • 89% of patients reported Rhopressa®was tolerated "well" or better in survey (mITT)

++Data on File

For Investor Use

7

U.S. Glaucoma Franchise Launch Update

	Actual Weekly Sales-Out to		IQVIA Weekly Data as of 12/4/2020
	Pharmacies Data as of 12/4/2020	20,000		19,046
			Franchise IQVIA
		18,000	Bottles
26,000		Rhopressa® IQVIA
	Franchise Actual Sales-Out to	24,039
24,000	Bottles
Pharmacies - Bottles
		16,000
22,000	Rhopressa® Actual Sales-Out to
	Pharmacies - Bottles
20,000		14,000
18,000				12,107
		15,67812,000
16,000
14,000		10,000
12,000
10,000		8,000
8,000		6,000
6,000
4,000		4,000

1/4/2019	12/4/2020	1/4/2019		12/4/2020
Rhopressa®has not been approved by any regulatory authorities other than the FDA and EMA and Rocklatan®has not been	For Investor Use	8
approved by any regulatory authority other than the FDA.

Advancing the Pipeline

Drug/Target Indication

Development Stage

Preclinical	Phase 1/2a	Phase 2b

Front of the Eye

AR-15512	Dry Eye
(AVX TRPM8 agonist)

Back of the Eye

AR-1105 Implant	RVO/DME
(Dexamethasone)
	wAMD
AR-13503 Implant	DME/DR
(ROCK, PKC)
	Glaucoma Neuro-
	enhancement

For Investor Use

9

U.S. Dry Eye Market: Under-diagnosed and Under-treated

US 2019 Sales: $1.6B est.

Cequa (Sun),

$46

Xiidra (TAK /

NVS), $409

Restasis (AGN),

$1,138

• Estimated 30 million dry eye sufferers in the United States; less than 3 million treated
• Dry eye related symptoms are one of the most common reasons for patients to visit an eye care professional
• Represents a significant health care burden, contributing to approximately 25% of visits to ophthalmic clinics
• Current pharmaceutical therapies areanti-inflammatories, often with poor maintenance on therapy and poor tolerability
• DED affects quality of life and interferes with reading, driving ability, computer use, work productivity and is associated with increased anxiety, stress and depression
• Unmet need for different MOAs, better tolerability, and treatment of symptoms

Sources: Mixture of public information, IQVIA , Market Scope and estimates - Feb 2020; Gayton JL. Clin Ophthalmol. 2009; 3:405-412.;	For Investor Use	10
Stonecipher KG et al. Ther Clin Risk Manag. 2013; Asrini Noor N. W J Opthalmol & Vision Res 2018.

AR-15512 for Dry Eye

• Novel Mechanism of Action - Modulation of Corneal TRPM8 receptors
• • Topical eye drop
  • TRPM8 receptor is a cold thermoreceptor ion channel located on corneal nerve endings
  • Reduced corneal temperature triggered by tear evaporation activates TRPM8 which leads to:
  • • Increased basal tear production (sign for DED)
    • A cooling sensation leading to reduction in discomfort / ocular pain (symptom for DED)
  • This dual mechanism of action is different than those of current prescription dry eye products and supports use as monotherapy as well in conjunction with approved products
• Basal tearing depending on TRPM8 stimulation is independent ofpain-evolved reflex tearing

Data on file.	For Investor Use	11
AR-15512 is a development stage product candidate and is not approved by any regulatory agency

AR-15512 (TRPM8 Agonist) for Dry Eye

How AR-15512

works

AR-15512

Ophthalmic

Solution

For Investor Use12

AR-15512 for Dry Eye

• Avizorex completed a Phase 2a study in early 2019 in 109 subjects
• • One concentration (0.0014%) and two dosing regimens (BID/TID) for 4 weeks were evaluated
  • Primary endpoint: % of patients ≥ 20 points change in symptoms questionnaire (SANDE)
  • Secondary endpoints:
  • • Schirmer's test (tear production)
    • Tear filmbreak-up-time (TBUT)
    • Corneal staining
• Key findings:
• • BID dosing demonstrated greater separation from vehicle, especially in subjects with higher symptoms at baseline
  • Statistical differences from vehicle observed in BID dosing≥arm in symptoms (severe subjects) and Schirmer's change 3 mm

Data on file.	For Investor Use	13
AR-15512 is a development stage product candidate and is not approved by any regulatory agency

AVX-012(AR-15512) Dry Eye Clinical Trial Highlights

• Significant efficacy achieved for sign and symptoms with BID dosing of 0.0014% (50µM)AVX-012(AR-15512) over 28 days

Symptoms: SANDE Score

Percentage of patients improving ≥20 score

p=0.021

p=0.1

	• Graph on the right represents primary endpoint with a
	subset of more severe symptoms
++Data on File	• Demonstrated statistical significance	For Investor Use	14

AVX-012(AR-15512) Dry Eye Clinical Trial Highlights

• Significant efficacy achieved for sign and symptoms with BID dosing of 0.0014% (50µM)AVX-012(AR-15512) over 28 days

Sign: Schirmer Evaluation

Percentage of patients improving ≥3mm

++Data on File	15
	For Investor Use

Dry Eye Program: AR-15512

• Target symptoms: significant step in addressing the symptoms of dry eye patients and providing a cooling sensation
• Impact basal tear production: production of natural tears and not just an acute reflex tear
• Safe forlong-term use
• Other approved products on the market:
• • Xiidra®: only approved product for the treatment of signs and symptoms
  • Restasis®, Cequa™ and TrueTear®: approved for increase in tear production

For Investor Use

16

AR-15512 Development Update

• Clinical Trial Series named "COMET" =Cold Thermoreceptor Modulation as an Effective Treatment
• Phase 2b clinical study commenced October 2020
• Phase 2b study is evaluating efficacy and safety of 0.0014% and 0.003% BID
• • 360 patients (1:1:1) for 3 months
  • Environmental and Controlled Adverse Environment (CAE) conditions
  • Primary endpoints: ocular discomfort (symptom) and tear production (sign)
  • Secondary endpoints include: SANDE, staining TBUT, changes post CAE

COMET-1 Phase 2b topline results expected Q3 2021

For Investor Use

17

2019 U.S. Retinal Disease Market

	2019 Sales: $6.8B		2019 Unit Sales: 8.1MM
Beovu,	steroids,	others,	Beovu,	steroids,	others,
$0.21	0.3	0.1
$0.04		0.03
		$0.02

Lucentis,

1.1

Lucentis,
$1.8	Eylea, 3.3

Eylea,

$4.6

Avastin,

$0.04

Avastin,

3.3

Sources: Mixture of public information, IQVIA, Market-Scope and estimates - Feb 2020

For Investor Use

18

Aerie's Lead Implant Product Candidates

AR-1105 (Dexamethasone) Implant (Phase 2 Topline reported July 2020)

• Indications under development: retinal vein occlusion (RVO)
• Target product profile vs. Ozurdex®
• • Designed for longer duration of efficacy (6 mo vs 3 mo)
  • Designed for improved administration due to smaller needle
  • Potential for fewer adverse effects due to lower peak drug levels

AR-13503 (ROCK/PKC) Implant (Topline data expected H2 2021)

• Initial indications under development: neovascular AMD and DME
• Novel MOA:anti-angiogenesis PLUS anti-fibrosis,anti-inflammation
• Designed to be effective as monotherapy or adjunctive therapy toanti-VEGF
• Targeting injection once every 6 months

For more information on Ozurdex® please see the product webpage https://www.ozurdex.com	For Investor Use 19
AR-1105 and AR-13503 are development stage product candidates and are not approved by any regulatory agency

AR-1105: Phase 2 Topline Summary

• The Phase 2 clinical trial(AR-1105-CS201) was conducted at 19 centers in the United States. A total of 49 patients completed the study.
• The objective of the Phase 2 clinical trial was to evaluate two formulations ofAR-1105, clinical formulation #1 (CF-1) and clinical formulation #2 (CF-2) with different steroid release profiles. The clinical trial was conducted in two stages.
  In the initial safety stage, five patients were enrolled in a single cohort to receive CF-1, delivering a 340µg dose of dexamethasone in a single intravitreal injection. In stage 2, 44 patients were randomized 1:1 to receive either CF-1 or CF-2.
• The results demonstrated positive and sustained treatment effects with both formulations as shown by increases in best corrected visual acuity and reductions in macular edema. Peak efficacy was observed earlier withCF-1, while CF-2 demonstrated a longer overall duration of effect of up to six months.
• Both formulations,CF-1 and CF-2, were well tolerated with no unexpected safety findings. Adverse events were consistent with other corticosteroid treatments and intravitreal injection procedures.

The profiles of the different cohorts demonstrate the flexibility of the

PRINT®sustained release technology platform in enhancing the management

and durability of treatment effects. Further details will be provided at an

upcoming ophthalmology conference.

Data on file.

For Investor Use

20

AR-1105: Opportunity Considerations

• The Diabetic Macular Edema market is expected to grow with increasing diabetes prevalence in the United States and abroad.
• The performance ofAR-1105 as indicated in the P2 topline data, which reflects six-month sustained delivery, may render this product, if approved, highly competitive in both the U.S. and European markets
• The potentially significant differentiation withsix-month sustained delivery, AR-1105 may be viewed positively in comparison to current products and potentially create a new treatment alternative to anti-VEGFnon-responders
• Aerie's exclusive PRINT®platform may allow for low-cost production and significant pricing flexibility
• Six-monthdosing may also benefit physician productivity and overall health economics
• Opportunity for market expansion - market currently $100+M in the U.S. and nearly $300M in Europe

The positive AR-1105 P2 topline sustained efficacy data points to the potential for a significant pipeline asset for Aerie, of particular value in Europe

AR-1105 is a development stage product candidate and is not approved by any regulatory agency

For Investor Use

21

Expanding Aerie Franchise: Japan

• Phase 2 study successful topline results released in November 2019
• First Phase 3 trial commenced in Japan in December 2020

Recently announced licensing agreement with Santen for Japan along with

rights for several other Asian countries

Sources: IMS Analytics link at ex-manufacturer price level and Unit-April 2020.*TRx calculated from IQVIA unit data (1 month = 1 TRx)	For Investor Use	22

AR-13324-CS208 Japan Phase 2 Study Topline Results

• 28-dayprospective, double-masked,placebo-controlled,dose-ranging study of netarsudil efficacy and safety in Japanese subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT)
• Netarsudil 0.01%, 0.02% and 0.04% were efficacious, met primary endpoint of superiority to placebo in mean diurnal IOP at Week 41, were safe and generally well tolerated
• • Baseline mean diurnal IOPs20-21 mmHg across study arms2(Japanese IOPs ~3 - 4 mmHg lower than in the U.S.)
  • Week 4 mean diurnal IOP was 16.3(-4.1), 15.4 (-4.8), 16.2 (-4.8) and 19.3 (-1.7) mmHg in the netarsudil 0.01%, 0.02%, 0.04%, and placebo groups, respectively2
  • No serious adverse events
• Netarsudil 0.02% (concentration of Rhopressa®in the U.S) provided best balance of efficacy and safety
• • Most common AE was Conjunctival Hyperemia (37.0%), discontinuation rate was 1.9%, all lower than in UStrials3-5

Netarsudil generated up to 4.8 mmHg reduction in IOP

from baseline

1. ANCOVA with MCMC imputation. 2. Observed data. 3. Bacharach J, et al. Ophthalmology. 2015 Feb;122(2):302-7. 4. Serle JB, et al. Am J Ophthalmol. 2018 Feb;186:116-127. 5. Khouri AS, et al. Am J Ophthalmol. 2019 Aug;204:97-104.

For Investor Use

23

AR-13324-CS208 Japan Phase 2 Study Topline Results

			Mean Diurnal IOP (ITT, Observed Data)
	24
	23
	22	21.1
		20.5		20.8
	21		20.3
SEM	20	19.8 19.3	19.3			Baseline
+	19
mmHg	18					Week 1
					Week 2
IOP	17
	16.3	15.9	15.7 15.7 16.2	Week 4
		16.215.9
	16			15.6 15.4
	15
	14
	13	Placebo	Netarsudil 0.01%	Netarsudil 0.02%	Netarsudil 0.04%
		(n=55)	(n=55)	(n=54)	(n=51)

• P<0.0001 vs. placebo at Week 4 for all dose levels1

• 0.02% achieved lowest mean diurnal IOP at Week 4	24

1. ANCOVA with MCMC imputation

For Investor Use

Expanding Aerie Franchise: Europe

• Marketing authorisation granted for Rhokiinsa®(Rhopressa®) in November 2019; Positive CHMP opinion for Roclanda®(Rocklatan®) received in November 2020, EMA approval expected late 2020 / early 2021
• Mercury 3: Reported successful90-day topline data in September 2020; Rocklatan®(known as Roclanda®in Europe) achieved non-inferiority to a fixed- dose combo in Europe (Ganfort®)
• Ireland Plant approved for U.S. production of Rhopressa®and Rocklatan®

Europe may represent Aerie's next collaboration opportunity

based upon current interest levels

Sources: IQVIA Midas data at ex-manufacturer price level and Unit-April 2020.*TRx calculated from IQVIA unit data (1 month = 1 TRx)	For Investor Use	25

Summary

• Key Priorities
• • Rhopressa®and Rocklatan®gaining momentum in the United States
• Globalization Strategy
• • Japan: Santen collaboration commencing and first Phase 3 trial underway
  • Europe: Interest expressed from potential collaborators
  • Ireland Manufacturing Facility approved for U.S. production of Rhopressa®and Rocklatan ®
• Research Initiatives
• • TRPM8 agonist for dry eye P2b commenced
  • Retina Program, includingAR-1105 prospects with positive P2 topline
• Well-Financed
• • $218.4M cash/investments at 9/30/20
  • Relatively low net cash used in operations of $22.4M forthird-quarter 2020
  • Santen upfront payment of $50M received infourth-quarter 2020

For Investor Use

26